BridgeBio Oncology (BBOT) Insider Option Grant of 499,731 Shares

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. (BBOT) reported an insider acquisition on Form 4 filed for reporting person Wallace Eli M., who is listed as both a director and the Chief Executive Officer. On 08/26/2025 the reporting person acquired a stock option to purchase 499,731 shares at an exercise price of $9.59. The option is subject to a time-based vesting schedule beginning August 11, 2025, with vesting over 48 months and a portion tied to the effectiveness of an S-8 registration; the full grant vests on the fourth anniversary of the vesting commencement date, subject to continued service. The Form 4 was signed by an attorney-in-fact on 08/28/2025.

Positive

• Insider acquisition disclosed: Reporting person acquired 499,731 stock options on 08/26/2025.
• Alignment with long-term incentives: Options vest over 48 months starting 08/11/2025 and include an S-8 registration contingency.

Negative

• None.

Insights

Financial Analyst

TL;DR: A senior insider received a sizable option grant that aligns compensation with long-term company performance.

The Form 4 discloses an acquisition of 499,731 stock options at a $9.59 exercise price by Wallace Eli M., identified as CEO and director. From a financial viewpoint, the grant size is material relative to a single insider award and will only benefit the holder if the underlying common stock appreciates above $9.59 before expiration. The vesting schedule links realized value to continued service and to an S-8 registration becoming effective for an initial portion, which delays immediate transferability for some shares. This structure commonly aims to retain leadership and tie pay to shareholder value creation.

Corporate Governance Expert

TL;DR: The disclosure shows a time-vested executive option grant with standard service and registration contingencies.

The filing identifies the reporting person as both director and CEO and documents a grant of 499,731 options exercisable at $9.59 with a four-year vesting schedule beginning August 11, 2025 and a portion contingent on an S-8 filing becoming effective. From a governance perspective, tying vesting to continued service and to registration for resale is a common practice to align executive incentives while managing secondary-market timing. The filing is procedural and provides the required Section 16 disclosure for insider compensation-related transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wallace Eli M.

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.59	08/26/2025		A		499,731		(1)	08/25/2035	Common Stock	499,731	$0	499,731	D

Explanation of Responses:

1. A fraction of the shares underlying such option equal to (x) the number of full months between August 11, 2025 ("Vesting Commencement Date") and the date on which a registration statement on Form S-8 is filed and effective with the Securities and Exchange Commission (the "S-8 Filing Date") divided by (y) 48 shall vest on the S-8 Filing Date, and 1/48th of the shares underlying such option shall vest each month thereafter on the day of the month corresponding to the Vesting Commencement Date (and if there is no suchcorresponding day for a month, then the vesting date shall be the last day of the applicable month) until 100% of the shares underlying such option is vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service the Issuer on each such vesting date.

	/s/ Aaron Chan, Attorney-in-Fact	08/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Wallace Eli M. report on Form 4 for BBOT?

He reported acquiring a stock option for 499,731 shares with an exercise price of $9.59 on 08/26/2025.

What are the vesting terms for the option grant disclosed in the Form 4?

Vesting begins on 08/11/2025, vests over 48 months with 1/48th monthly thereafter, and a fraction vests upon effectiveness of an S-8 filing; full vesting occurs on the fourth anniversary, subject to continued service.

What positions does the reporting person hold at BridgeBio Oncology Therapeutics?

The Form 4 lists Wallace Eli M. as a Director and the Chief Executive Officer of the issuer.

When was the Form 4 signed and by whom?

The form was signed by Aaron Chan, Attorney-in-Fact on 08/28/2025.

What is the exercise price and expiration detail shown for the option?

The disclosed exercise price is $9.59; the filing lists the option and the underlying 499,731 shares of common stock. (The filing shows an expiration-related date in the table.)